Gilead‘s product sales fueled the significant increase in revenue and profit. Its total product sales for the fourth quarter of FY 2014 were $7.2 billion compared to $3 billion for the fourth quarter the year prior.
Driven by sales of hepatitis C drugs Sovaldi and Harvoni, Gilead’s antiviral product sales skyrocketed in the fourth quarter of 2014 to $6.7 billion, up from $2.6 billion for the same period of 2013.
More articles on healthcare finance:
CFO vs. CIO: Bridging the gap in perspective
10 pieces of advice hospital CFOs shared this month
5 CFOs in the headlines this week
